TREVI THERAPEUTICS INC (TRVI) Stock Price, Forecast & Analysis
NASDAQ:TRVI • US89532M1018
TRVI Key Statistics, Chart & Performance
The current stock price of TRVI is 11.92 USD. In the past month the price increased by 11.32%. In the past year, price increased by 163.27%.
TRVI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TRVI. When comparing the yearly performance of all stocks, TRVI is one of the better performing stocks in the market, outperforming 94.89% of all stocks.
TRVI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRVI. No worries on liquidiy or solvency for TRVI as it has an excellent financial health rating, but there are worries on the profitability.
TRVI Financial Highlights
Over the last trailing twelve months TRVI reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 15.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23% | ||
| ROE | -24.16% | ||
| Debt/Equity | 0 |
TRVI Forecast & Estimates
18 analysts have analysed TRVI and the average price target is 21.51 USD. This implies a price increase of 80.41% is expected in the next year compared to the current price of 11.92.
TRVI Ownership
TRVI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TRVI
Company Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 26 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Company Info
TREVI THERAPEUTICS INC
195 Church Street, 16Th Floor
New Haven CONNECTICUT 06510 US
CEO: Jennifer Good
Employees: 26
Phone: 18004831140
TREVI THERAPEUTICS INC / TRVI FAQ
Can you describe the business of TREVI THERAPEUTICS INC?
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 26 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
What is the current price of TRVI stock?
The current stock price of TRVI is 11.92 USD. The price increased by 3.47% in the last trading session.
What is the dividend status of TREVI THERAPEUTICS INC?
TRVI does not pay a dividend.
What is the ChartMill rating of TREVI THERAPEUTICS INC stock?
TRVI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about TREVI THERAPEUTICS INC (TRVI) stock?
18 analysts have analysed TRVI and the average price target is 21.51 USD. This implies a price increase of 80.41% is expected in the next year compared to the current price of 11.92.
Can you provide the sector and industry classification for TREVI THERAPEUTICS INC?
TREVI THERAPEUTICS INC (TRVI) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does TREVI THERAPEUTICS INC have?
TREVI THERAPEUTICS INC (TRVI) currently has 26 employees.